Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

GSK-3

Glycogen synthase kinase 3 is a serine/threonine protein kinase that mediates the addition of phosphate molecules onto serine and threonine amino acid residues. First discovered in 1980 as a regulatory kinase for its namesake, Glycogen synthase, GSK-3 has since been identified as a kinase for over 100 different proteins in a variety of different pathways. In mammals GSK-3 is encoded by two paralogous genes, GSK-3 alpha (GSK3A) and GSK-3 beta (GSK3B). GSK-3 has recently been the subject of much research because it has been implicated in a number of diseases, including Type II diabetes (diabetes mellitus type 2), Alzheimer's disease, inflammation, cancer, and bipolar disorder.

  • CHIR-99021
    T2310252917-06-9
    CHIR-99021 (CT99021) is an activator of the Wnt/β-catenin signaling pathway and a GSK-3α/β inhibitor (IC50=10/6.7 nM) with selective and oral activity.CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.
    • $36
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • GSK-3 Inhibitor 5
    T7755420099-89-2
    GSK-3 Inhibitor 5 (4-Cyanophenacyl bromide) is a ketone derivative that is used as an intermediate in pharmaceuticals and organic synthesis, and inhibits glycogen synthase kinase 3 (GSK-3).
    • $29
    In Stock
    Size
    QTY
  • Citric acid trilithium salt tetrahydrate
    T02566080-58-6
    Citric acid trilithium salt tetrahydrate (Lithium citrate tribasic tetrahydrate) , the active component of Lithium, is a medicine used in the therapy of psychiatric disease. It has shown the effects of signaling pathways and metabolic in the brain based on the particular disease and clinical condition model. According to the reports, Citric acid trilithium salt tetrahydrate was used as a mood stabilizer when treating bipolar mood disorders (BD) and lower the risk of self-harm in BD patient. In addition,Citric acid trilithium salt tetrahydrate has been the choice drug in the therapy of acute manic episodes.Citric acid trilithium salt tetrahydrate also could dissolve uric acid crystals in urine achieved from patients with gout. Besides,Citric acid trilithium salt tetrahydrate have some dose-dependent side-effects. The the main side-effects of Lithium Citrate is the tendency to inhibit the prostatic acid phosphatase enzyme (PAP), which result in the accumulation of PAP.
    • $29
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • 4-Chloro-2'-bromoacetophenone
    T8908536-38-9
    4-Chloro-2'-bromoacetophenone against glycogen synthase kinase-3 (GSK-3beta).
    • $50
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Cyanoacetohydrazide
    T0704140-87-4
    Cyanoacetohydrazide (Cyanoacetic hydrazide) is an anti-TB drug. It has also been used to derive compounds that may have antitumor properties.
    • $29
    In Stock
    Size
    QTY
  • 5-Bromoindole
    T747310075-50-0
    5-bromoindole is a potential inhibitor of glycogen synthase kinase 3 (GSK-3)and an important pharmaceutical chemical intermediate
    • $39
    In Stock
    Size
    QTY
  • Cromolyn sodium
    T126015826-37-6
    Cromolyn sodium (FPL-670) is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells.
    • $48
    In Stock
    Size
    QTY
  • 3F8
    T22180159109-11-2
    3F8 is a selective GSK-3β inhibitor that can be used as a new tool and potential therapeutic candidate compound for GSK3-related diseases, and can be used in the study of neurological disorders and cancer.
    • $115
    In Stock
    Size
    QTY
  • GSK3a-IN-38
    T776711062138-03-7
    GSK3a-IN-38 is a novel small molecule compound that has inhibitory effects on GSK-3a.
    • $195
    In Stock
    Size
    QTY
  • GS87
    T8605919936-70-2
    GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.
    • $133
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • GSK-3 inhibitor 3
    T773422227279-84-5In house
    GSK-3 inhibitor 3 is a selective, orally active, brain-permeable GSK-3 inhibitor that inhibits GSK-3α and GSK-3β with IC50s of 0.35 nM and 0.25 nM, respectively.GSK-3 inhibitor 3 reduces the phosphorylation level of tau protein S396 with an IC50 of 10 nM in a triple transgenic mouse model of Alzheimer's disease. GSK-3 inhibitor 3 reduced the phosphorylation level of tau protein S396 in a triple transgenic mouse model of Alzheimer's disease, with an IC50 of 10 nM.GSK-3 inhibitor 3 can be used for the study of neurological diseases.
    • $195
    In Stock
    Size
    QTY
  • PHA-767491
    T6206845714-00-3
    PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • MBM-55S
    T119612083624-07-9
    MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer cells. MBM-55S shows antitumor activities.
    • $195
    In Stock
    Size
    QTY
  • Aloisine B
    T69188496864-14-3In house
    Aloisine B (AloisineB) inhibited cyclin-dependent kinase and glycogen synthase kinase with IC50 values of 0.85 µM and 0.75 µM, respectively. Aloisine B has antiviral activity and can be used to study Alzheimer's, diabetes, HIV and Parkinson's.
    • $350
    In Stock
    Size
    QTY
  • GSK3-IN-2
    T73270380450-97-5
    GSK3-IN-2 is a potent GSK3 inhibitor for the treatment of diabetes and neurodegenerative diseases.
    • $72
    In Stock
    Size
    QTY
  • GSK-3 inhibitor 4
    T773412227279-83-4
    GSK-3 inhibitor 4 is an orally active and brain-permeable compound that acts as a triple inhibitor of GSK-3, CDK2, and CDK5, with IC50 values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM (CDK2), and 0.68 μM (CDK5). It effectively reduces Tau protein levels and can be used in the study of Alzheimer's disease.
    • $350
    In Stock
    Size
    QTY
  • Ceftriaxone Sodium
    T66175958633-51-7
    Ceftriaxone Sodium is a broad-spectrum β-lactam tertiary cephalosporin antibiotic with anti-inflammatory, antitumor, antibacterial, and antioxidant activities.Ceftriaxone Sodium is a covalent GSK3β and Aurora B inhibitor used in the study of sepsis and infective endocarditis.
    • $39
    Backorder
    Size
    QTY
    TargetMol | Citations Cited
  • GSK-3β inhibitor 12
    T60472784170-07-6
    GSK-3β inhibitor 12 is a selective GSK-3β inhibitor.GSK-3β inhibitor 12 inhibits 49.11% of 25 μM GSK-3β activity and 37.11% of 50 μM GSK-3β activity.GSK-3β inhibitor 12 can be used for the study of Parkinson's in the presence of lipopolysaccharide induction.
    • $83
    In Stock
    Size
    QTY
  • GSK3-IN-4
    T64366748145-19-9
    GSK3-IN-4 is a GSK-3 inhibitor with IC50 of 0.101-1 μM of GSK-3α and GSK-3β in Calipe Assay.
    • $117
    In Stock
    Size
    QTY
  • CDK8-IN-12
    T720482613307-67-6
    CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent. CDK8-IN-12 inhibits GSK-3α, GSK-3β and PCK-θ with Ki of 13 nM, 4 nM and 109 nM respectively. CDK8-IN-12 showed anti-proliferative activity against MV4-11 cells.
    • $79
    In Stock
    Size
    QTY
  • GSK-3β inhibitor 8
    T355561139875-74-3In house
    GSK-3β inhibitor 8 (GSK3β Inhibitor XVIII) is a potent and selective GSK-3β inhibitor with an IC50 value of 64 nM.GSK-3β inhibitor 8 is a thienopyrimidine derivative that negatively regulates the Wnt signaling pathway and stimulates β-cell proliferation.
    • $110
    35 days
    Size
    QTY
  • ARN25068
    T613602649882-80-2
    ARN25068 is a potent inhibitor of GSK-3β, FYN, and DYRK1A protein kinases, exerting its activity in the sub-micromolar range. This compound effectively addresses tau hyperphosphorylation [1].
    • $115
    In Stock
    Size
    QTY
  • GSK-3 inhibitor 1
    T11468603272-51-1
    GSK-3 inhibitor 1 is a GSK-3 inhibitor.
    • $106
    In Stock
    Size
    QTY
  • 5-Iodo-indirubin-3'-monoxime
    T10172331467-03-9
    5-Iodo-indirubin-3'-monoxime is a potent inhibitor of GSK-3β, CDK5 P25, and CDK1 cyclin B, competing with ATP for binding to the catalytic site of the kinase (IC50s: 9, 20, and 25 nM).
    • $297
    Backorder
    Size
    QTY
  • GSK-3 Inhibitor XIII
    T78578404828-14-4
    GSK-3 Inhibitor XIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.
    • $169
    In Stock
    Size
    QTY
  • EHT 1610
    T152041425945-60-3
    EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively. EHT 1610 has an inhibitory effect on leukemia, regulating cell cycle and inducing cell apoptosis.
    • $147
    In Stock
    Size
    QTY
  • GNF4877
    T114472041073-22-5
    GNF4877 is a potent inhibitor of DYRK1A and GSK3β (IC50s: 6 nM and 16 nM, respectively), resulting in the blockade of nuclear export of nuclear factor of activated T-cells (NFATc) and increased β-cell proliferation.
    • $127
    In Stock
    Size
    QTY
  • R547
    T6312741713-40-6
    R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1 2 4 with Ki of 2 nM 3 nM 1 nM. It is less potent to CDK7 and GSK3α β, while inactive to other kinases. Phase 1.
    • $45
    In Stock
    Size
    QTY
  • Tideglusib
    T3067865854-05-3
    Tideglusib (NP031112), a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3), is with anti-inflammatory and neuroprotective activities.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • CHIR-99021 HCl
    T2310L1797989-42-4
    CHIR-99021 HCl (Laduviglusib HCl) is a highly potent and selective inhibitor of GSK-3α β, with IC50 values of 10 nM and 6.7 nM respectively. It demonstrates remarkable selectivity for GSK-3, with over 500-fold selectivity over CDC2, ERK2, and other protein kinases. Additionally, CHIR-99021 HCl serves as a robust activator of the Wnt β-catenin signaling pathway. Moreover, it exhibits the ability to enhance self-renewal in both mouse and human embryonic stem cells. Furthermore, CHIR-99021 HCl induces autophagy [1] [2] [3].
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • AR-A014418
    T1881487021-52-3
    AR-A014418 (GSK 3β inhibitor VIII) is an ATP-competitive, and selective GSK3β inhibitor.
    • $45
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • TBB
    T269517374-26-4
    TBB (NSC-231634)(NSC-231634) is a highly selective, ATP GTP-competitive inhibitor of casein kinase-2 (CK2).
    • $38
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • SNS-032
    T6049345627-80-7
    SNS-032 (BMS-387032) is a selective inhibitor of CDK2 (IC50: 48 nM), exhibiting 10- and 20-fold selectivity over CDK1 and CDK4, respectively. It is also sensitive to CDK7 (IC50: 62 nM) and CDK9 (IC50: 4 nM), with no effect on CDK6.
    • $43
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • AZD1080
    T1741612487-72-6
    AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor.
    • $36
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • SB 216763
    T3077280744-09-4
    SB 216763 (SB216763) is an effective and specific GSK-3α/β inhibitor (IC50: 34.3 nM).
    • $33
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • KenPaullone
    T2247142273-20-9
    KenPaullone (9-Bromopaullone), a potent CDK1, CDK2 and CDK5 inhibitor, as new enhancer for iTreg cell differentiation. Kenpaullone promotes iTreg cell differentiation through increased and prolonged transcription of foxp3 gene by enhancing TGFβ-Smad3 signaling pathway.
    • $32
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • GSK 3 Inhibitor IX
    T1917667463-62-9
    GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.
    • $37
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • AT7519
    T6205844442-38-2
    AT7519 is a CDK1 2 4 6 9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
    • $52
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Excisanin A
    TN404678536-37-5
    ExcisaninA may be a potent inhibitor of AKT signaling pathway in tumor cells, it can inhibit invasion by suppressing MMP-2 and MMP-9 expression, it may be a potential anti-metastatic chemotherapeutic agent for the treatment of breast cancer. Excisanin A shows comparable inhibitory effects on the LPS-induced production of NO and PGE2, and activation of NF-kappaB without affecting cell viability.Excisanin A induces apoptosis in colon cancer cell line SW620 as determined by Annexin V staining, the cleavage of caspase-3 and the proteolytic degradation of poly (ADP-ribose) polymerase (PARP).
    • $980
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • KY19382
    T90252226664-93-1
    KY19382 (2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-Ky19382) is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β( IC50s of 19 and 10 nM, respectively). It activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases.
    • $100
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AT7519 Hydrochloride
    T1778902135-91-5
    AT7519 Hydrochloride (AT7519 HCl) is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9.
    • $52
    In Stock
    Size
    QTY
  • GSK3-IN-1
    T9987478482-74-5
    GSK3-IN-1 is a GSK3B-glycogen synthase kinase-3 beta inhibitor.
    • $44
    In Stock
    Size
    QTY
  • LY2090314
    T1755603288-22-8
    LY2090314, an effective GSK-3α/β inhibitor (IC50: 1.5 nM/0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.
    • $41
    In Stock
    Size
    QTY
  • CHIR-98014
    T2608252935-94-7
    CHIR-98014 (CT98014) is a selective GSK3 inhibitor; potentiate insulin activation of glucose transport and utilization in vitro and in vivo.
    • $68
    In Stock
    Size
    QTY
  • MeBIO
    T21966667463-95-8
    MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.
    • $33
    In Stock
    Size
    QTY
  • ALSTERPAULLONE
    T7426237430-03-4
    Alsterpaullone is a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells Through Apoptosis-Inducing Effec
    • $89
    In Stock
    Size
    QTY
  • CHIR-124
    T6350405168-58-3
    CHIR-124 is an effective Chk1 inhibitor (IC50: 0.3 nM). It has 2, 000-fold selectivity against Chk2, 500- to 5, 000-fold less activity against Cdc2 and CDK2/4.
    • $35
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BRD0705
    T106062056261-41-5
    BRD0705 is a potent, orally active GSK3α inhibitor with high selectivity (IC50: 66 nM; Kd: 4.8 μM), demonstrating an 8-fold higher selectivity for GSK3α compared to GSK3β (IC50: 515 nM).
    • $151
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Indirubin-3′-oxime
    T9138667463-82-3
    Indirubin-3′-oxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.
    • $39
    In Stock
    Size
    QTY
  • (E/Z)-GSK-3β inhibitor 1
    T91783367-88-2
    (E Z)-GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor demonstrating high antidiabetic efficacy.
    • $53
    In Stock
    Size
    QTY